TABLE 1.
Some of the clinical trials for CAR‐T‐cell therapy of hematological malignancies.
| Clinical trial | Phase | Start date | Estimated completion date | Disease | Estimated participants | Ages eligible | Target antigen | Location |
|---|---|---|---|---|---|---|---|---|
| NCT04599556 | I/II | 2020 | 2023 | ALL | 108 | 3–70 years (child, adult, older adult) | CD7 | China |
| NCT01044069 | I | 2010 | 2023 | ALL | 93 | 18 ≤ years (adult, older adult) | CD19 | United states |
| NCT02028455 | I/II | 2014 | 2036 | ALL | 167 | 1–26 years (child, adult) | CD19 | United States |
| NCT02772198 | I/II | 2016 | 2022 | ALL | 300 | 1–50 years (child, adult) | CD19 | Israel |
| NCT02435849 | II | 2015 | 2022 | ALL | 97 | 25 ≤ years (adult, older adult) | CD19 | United States |
| NCT01029366 | I | 2010 | 2016 | CLL | 26 | 18 ≤ years (adult, older adult) | CD19 | United States |
| NCT01416974 | I | 2011 | 2019 | CLL | 13 | 18 ≤ years (adult, older adult) | CD19 | United States |
| NCT01865617 | I/II | 2013 | 2021 | CLL | 204 | 18 ≤ years (adult, older adult) | CD19 | United States |
| NCT03331198 | I/II | 2017 | 2026 | CLL | 259 | 18 ≤ years (adult, older adult) | CD19 | United States |
| NCT00924326 | I | 2009 | 2021 | DLBCL | 43 | 18–70 years (adult, older adult) | CD19 | United States |
| NCT02631044 | I | 2016 | 2022 | DLBCL | 314 | 18 ≤ years (adult, older adult) | CD19 | United States |
| NCT02348216 | I/II | 2015 | 2035 | DLBCL | 307 | 18 ≤ years (adult, older adult) | CD19 | United States |
| NCT02445248 | II | 2015 | 2023 | DLBCL | 115 | 18 ≤ years (adult, older adult) | CD19 | United States |
| NCT02215967 | I | 2014 | 2019 | MM | 30 | 18–73 years (adult, older adult) | BCMA | United States |
| NCT02658929 | I | 2015 | 2022 | MM | 67 | 18 ≤ years (adult, older adult) | BCMA | United States |
| NCT03958656 | I | 2019 | 2021 | MM | 13 | 18–73 years (Adult, Older Adult) | SLAM7 | United States |
| NCT04288726 | I | 2020 | 2037 | LH | 18 | 12–75 years (child, adult, older adult) | CD30 | United States |
| NCT04136275 | I | 2020 | 2024 | LH | 18 | 18 ≤ years (adult, older adult) | CD37 | United States |
| NCT03904069 | I | 2022 | 2029 | AML | 40 | 12 ≤ years (child, adult, older adult) | FLT3 | United States |
| NCT03081910 | I | 2017 | 2039 | T‐ALL | 42 | 75 ≤ years (child, adult, older adult) | CD5 | United States |
Abbreviations: ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B‐cell lymphoma; MM, multiple myeloma; HL, Hodgkin lymphoma; AML, acute myeloid leukemia; T‐ALL, T‐cell acute lymphoblastic leukemia.